Skip to content

Maternal Non-Stress Testing

Wireless Wearable Maternal Fetal Sensors for Non-Stress Testing

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04343482
Enrollment
91
Registered
2020-04-13
Start date
2018-04-01
Completion date
2022-09-06
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women

Brief summary

Percent agreement of vital signs monitoring between the experimental sensor and standard of care monitoring

Interventions

vital signs monitoring during maternal non-stress testing

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* Maternal age \>18 years old * Pregnant mothers \>26 weeks undergoing nonstress testing or delivering * Singleton pregnancy * No fetal abnormality or chromosomal abnormality * Subjects willing and able to comply with requirements of the protocol * Nurses and clinicians who will be administering the non-stress test to the pregnant subject

Exclusion criteria

* Women who refuse to signed the informed consent form * Maternal age under 18 years old * Multiple pregnancy * Known major fetal malformation or chromosomal abnormality * Medical or obstetric problem that would preclude the use of abdominal electrodes * Inability to consent to this study due to medical illness, diminished intellectual capacity, or language barrier * Women using pacemakers

Design outcomes

Primary

MeasureTime frameDescription
Device comparison to standard monitoring3 yearsThe primary outcome measure is concordance of FHR tracing assessments from Rogers sensor recordings with those obtained from the current standard of care electronic fetal monitoring systems.

Secondary

MeasureTime frameDescription
Qualitative analyses of sensor output3 yearsQualitative analyses of FHR, MHR, BP, pulse oximetry, and UC data capture from the sensors will be performed for the purpose of optimizing signal-to-noise filtering of raw data collected during the study. Any adverse events will be recorded such as skin irritation (expected to be negligible).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026